

Index

```
abortion, previous 11–12
                                                     albumin, serum levels 283
academic infrastructure 313-14
                                                     alcohol abuse 16
acidosis, neonatal 227
                                                        social deprivation 156
  hypoxia 270-1
                                                     alcohol consumption 15, 16
  metabolic 277
                                                     alpha fetoprotein (AFP), maternal serum 145-6
actin 28
                                                     ambulatory monitoring, maternal 319
activating transcription factor family (ATF) 93-4
                                                     amnio drainage 217
activator protein 1(AP-1) 94-5
                                                     amniocentesis, materno-fetal infection diagnosis
  NF-\kappaB cross-coupling 95
                                                          172 - 3
cyclic adenosine monophosphate (cAMP) 30
                                                     amnioinfusion 183
  signalling 93-4
                                                     amnion 48-9, 49-50
                                                        prostaglandin source 84
cyclic adenosine monophosphate response element-
    binding protein (CREB) 85-6, 93-4
                                                     amniopatch 183
cyclic adenosine monophosphate response elements
                                                     amniotic fluid
    (CRE) 85-6
                                                        culture 172-3
adolescence
                                                          positive 8-9, 173
  outcomes 127
                                                        proinflammatory cytokines in infections 144
                                                        volume 177-8
  respiratory symptoms 122-3
adrenal insufficiency, steroid therapy 203
                                                      anaemia of prematurity 280
adrenaline
                                                        risk factors 280
  dosing regimes 270
                                                      anaesthesia
  hypotension 277
                                                        Caesarean section 245
  mode of administration 270
                                                        corticosteroid use 249
  neonatal resuscitation 270
                                                        fetal heart rate 237
\beta-adrenergic agents 223–4
                                                        fetal monitoring 237
  anaesthesia in preterm labour 250-1
                                                        general 235
  see also \beta sympathomimetics
                                                          avoidance 256
β2-adrenergic receptor agonists 160
                                                          cardiovascular changes 242
adrenergic receptors 30
                                                          pre-eclampsia 245
adult respiratory distress syndrome (ARDS) 243-4
                                                        ideal 254-7
adults, outcomes 127
                                                        inevitable delivery 248-9, 253
advance authorisations 324-5
                                                        local 238-9
age
                                                        miscarriage risk 237
                                                        planned preterm delivery 239-48
  at death 112-13
  see also gestational age
                                                        premature delivery risk 237
airway, resuscitation 265-6
                                                        preterm labour 249-52
```

397



anaesthesia (cont.)	assault 330
provision 252–7	treatment as 380
regional 239	assisted reproduction 4-5, 12-13
Caesarean section 245	multiple births 114
choice 256	asthma, maternal 246
hypotension 251	atosiban 160, 197–8
restrictive lung disease 246-7	anaesthetic implications 252
risks 235	multiple pregnancies 217
surgery during pregnancy 239	pre-eclampsia 223–4
tocolysis 249–52	attention deficit hyperactivity disorder (ADHD)
anaesthetic management 236	124–5
liaison with team 240	autism, retinopathy of prematurity
anaesthetists 235, 239	125–6
expertise 242	autoregulation 289
planned preterm delivery 240	
preterm delivery risk factors 248	β sympathomimetics 182, 195–7
analgesic management 236	anaesthesia in preterm labour 250–1
ideal 254–7	contraindications 196–7
incidental effects 371–2	diabetes mellitus 196–7
patient-controlled analgesia 238–9	medical emergencies 237
provision 252–7	multiple pregnancies 217
spinal analgesia 242	pulmonary oedema 217
timing 253	Baby Alexandra case 373–4
see also epidural analgesia	bacteraemia, fetal 173
anandamide (ANAN) 156	bacterial endotoxin 55–6, 79–80, 83
anhydramnios 194	fetal exposure 182
annexins 79	bacterial vaginosis 6–7
antenatal care 17–18, 154–5	bacteriuria 55–6
antepartum haemorrhage 159 antibiotics	asymptomatic 9–10, 158
	bag and mask device 266
hazards of use 181	bed occupancy 309–10
as medical treatment 384	bed rest, multiple pregnancies 212–13
neonatal infections 286	behavioural outcomes, school age
pPROM 180–1, 204	children 123–6,
preterm labour prevention 56, 204	benzodiazepines 237
prophylactic 164	bereavement damages 353
pPROM 180–1	best interests of child 373–5, 377
anticoagulation, maternal 246	rejection in Scotland 342–3
antiphospholipid syndrome 17	betamethasone 182–3
antiprogesterones 45–6	lung maturation enhancement 183
labour onset 53–4	maternal therapy 202–3
anxiety, maternal 237, 239	birth
anxiolytics 237	management 338–9
apoptosis	NHS Redress Scheme for injuries 358
cervical ripening 48	wrongful 352
membrane rupture 51	birthweight 109
arachidonic acid 55-6, 77-8, 83	economics of low 318
arachidonoyl ethanolamine (AEA) 156	outcome 110
Arthur case 369–70	see also extremely low birthweight babies; very
aspirin, anaesthetic implications 251	low birthweight babies



Bland case 369, 370–2	intracranial trauma risk 254
feeding 384	IUGR 228
bleeding, acute episodes in neonates 280	maternal hypertension 242-3
blindness 117, 118–19, 121	multiple births 218
body weight	diamniotic preterm first twin breech 220
maternal 16	diamniotic very low birth weight 219
neonates 272, 277	higher order 220–1
monitoring 277	limits of viability 221
Bolam test 331, 347-8	placental abruption 216
Bolitho case 348	refusal 338
Bowen, Jaimee (case) 378, 392	viability limits 178–9
brain, fetal	caffeine intake 16–17
acquired disorders 287–90	calcitonin gene-related peptide (CGRP) 30
development 288	calcium, uterine contractions 28–9
postnatal steroids 274–5	calcium channel(s) 29
injury 116, 122	receptor-operated 32–3
perinatal 175–6	calcium channel blockers 160, 198–9
vulnerability 292	anaesthetic implications 252
white matter 175–6, 183	multiple pregnancies 217
sensitisation to hypoxia-ischaemia 184	calcium-calmodulin 28
white matter	cannabis 156
injury 175–6, 183	capnography 239
vulnerability to injury 292	carbon dioxide pneumoperitoneum 239
brain, maternal	cardiac arrest in pregnancy 245–6
brain death 246	cardiac compression, internal 245–6
damage and intrauterine death in multiple	cardiac disease, maternal 241–2
pregnancy 216–17	cardiac transplantation 247–8
breathing, neonates	cardiopulmonary resuscitation, maternal 245–6
air versus oxygen 267	cardiotocography 227
resuscitation 266–8	contraction strength 191
see also ventilated babies, surfactant therapy;	erroneous interpretation 237
ventilation, mechanical	immature fetal cardiovascular physiology
breaths, rescue 266	204–5
breech delivery 323–4	cardiovascular system, neonates 275–7
mode in preterm 205	cardioversion, direct current 245–6
bronchopulmonary dysplasia see lung disease,	care
chronic	breach of 372
bupivacaine 255	obligation for dying with dignity 388
bupivacame 255	see also duty of care
Caesarean section 5–6	carotid artery, internal 288
anaesthesia 245	
provision 253	catecholamines, endogenous 237
combined surgical procedures 241	causation 348, 351–2 C/EBP family 81
communication necessity 255–6	,
counselling 323–4	C/EBP site on COX-2 gene 85–6
elective 205	cephalosporins 181
IUGR 228	cerebral arteries, pattern 288
	cerebral palsy 118, 175–6
pre-eclampsia 225 hypoxic fetal stress avoidance 184–5	causation 351
internal cardiac compression 245–6	quadruplet risk 220–1
111C11101 C01U10C C0111D1E381011 44J=0	LISK III IIIOHOCHOHOHIC IWIIIS / 9 1



cerebral palsy (cont.)	children
spastic 184	competence 343–5
triplet risk 220–1	legal recognition 366, 389-90
cerebrovascular accidents, pre-eclampsia	terminally ill 375
223	Chlamydia trachomatis 7–8, 55–6
cervical cerclage 163-4, 183-4	chondroitin sulphate 38-9, 41
emergency 201	chorioamnionitis 8–9, 174–5, 175–7
multiple births 221	amniotic fluid volume 177–8
multiple pregnancies 211–12, 213	expectant management 179
cervical index 137	multiple pregnancies 216, 221
cervical length 163-4	periventricular leukomalacia 291–2
digital examination 136	preterm delivery risk 248–9
fetal fibronectin combination 147	subclinical 173
high-risk women 140	temperature increase 248–9
measurement 138	treatment 181
cost effectiveness 320	chorion 48–50
mid-trimester 138	chorionicity 210
multiple pregnancies 141, 211–12	circulation, neonates 268
predictive ability 139–42,	clindamycin, mode of action 181
predictive value 146	clinical judgement 378
threatened preterm labour 141	clinical trials, parental agreement 377
ultrasound imaging 163–4, 171–2, 193	clomiphene 12–13
cervical os, internal	Clostridium difficile 181
	clotting screen, intrauterine death
opening 171–2	216–17
ultrasound-identified dilatation 193	
cervical ripening 37–48	clumsiness see dyspraxia
collagen structure 89–92	coagulopathy in pre-eclampsia 244–5
control 43–8	co-amoxiclav 180–1
cervical stitch retention 183–4	hazards of use 181
cervical therapy 163–4	necrotising enterocolitis 181
cervix	preterm labour use 204
appearance change 137–8	cognitive ability
dilatation 171–2	school age children 123-4
funnel length/width 137	collagen
funnelling 137, 171–2, 211–12	cervical ripening 89–92
incompetence 10	cervical structure 38–9, 40
myometrial contractions 89-92	fetal membranes 48–50
pregnancy 35, 39–42	fibroblast production 45
relaxin in maturation 143–4	collagen graft 183
secretions 134–5	collagenases 9, 36–7, 40, 89–92
smooth muscle 39	relaxin stimulation 143-4
structure 38–9	colony-stimulating factors 286
suprapubic pressure 137–8	common law
transfundal pressure 137–8	competence 340
ultrasound imaging 136-42	Scotland 356-7
dilatation 171–2	compensation, loss of good outcome
transvaginal 159–60	351–2
chest compressions 268	competence 339–45
child destruction offence 390–1	absence 340–2
childbearing, delayed 4	children 343–5



common law 340	labour 323–4
treatment refusal 343-4	preliminary discussion 323
young people 343–5	pre-pregnancy 159-60
complications, development 377	resuscitation 324-5
Congenital Disabilities (Civil Liability) Act (1976)	transfer 324
353, 354	courts
liability under 355–6	authorisation of course of action 378
congenital malformations, lethal 115	doctors' professional judgement 377-8
connective tissue disorders 158	CRE modulator protein (CREM) 93-4
connexin-26 27–8	C-reactive protein 173
connexin-43 27–8	neonates 284–5
gene 94	pregnancy risk 194
upregulation in labour 96	creatinine, maternal levels 247
consent 329–32	criminal law limitations 368-72
legal validity 330	critical care services 312
parental 366–8	cryoprecipitate 183
consultants 312–14,	cryotherapy, retinopathy of prematurity 287
continuous positive airway pressure (CPAP) 267-8,	cyclo-oxygenase (COX) 33-4, 77-8, 83-6
274	cyclo-oxygenase 1 (COX-1) 200
contraction-associated proteins 76	cyclo-oxygenase 2(COX-2)
contractions, preterm 144	gene C/EBP site 85–6
cord entanglement 220	gene expression in uterine tissue 85
multiple births 220–1	gene induction 85–6
cordocentesis 173	myometrial expression 84-5
IUGR 227	promoter 85, 85–6
corticosteroids	role in labour 83–6
anaesthesia in preterm labour 249	selective prostaglandin inhibitors 200
antenatal use 111–12, 182–3, 271	transcription mediation 86
contraindications 203	cyclo-oxygenase 2 (COX-2) inhibitors
fetal lung maturity 223-4	161, 200
gestational age 203	cyclosporin 247–8
IUGR 227	cytokines
magnesium sulphate combination 224-5	cascade 55–6
maternal therapy 202-3	inflammatory 9
multiple pregnancies 214–16	cervical changes 76-7
postnatal 274–5	fetal exposure 182
repeated doses 202-3	predictive value 144–5
surfactant therapy 203	myometrial contraction 34
corticotrophin-releasing hormone	neonatal assay 285
labour onset 54	pro-inflammatory 36-7, 46-7, 176-7
predictive value 143	periventricular leukomalacia 175-6
prostaglandin synthesis stimulation 85	
corticotrophin-releasing hormone receptors 54	damages
corticotrophin-releasing hormone-binding protein	Scottish law 356–7
(CRH-BP) 54	wrongful life actions 353
cortisol, labour onset 52–3	death
cost effectiveness of management strategies 318–20	acceleration 383-4
costs in negligence claims 357-9	age at 112–13
counselling 295–6, 320–5	allowing 370–1
Caesarean section 323-4	dignified 383-4 388



```
decision-making
                                                      disclosure, doctors to patients 331-2
  parents 367
                                                      disease, right of action 354-5
    involvement 367-8
                                                      disseminated intravascular coagulation (DIC)
  proxy 365
                                                        intrauterine death 216-17
  quality of life 375-6
                                                        pre-eclampsia 244-5
  treatment 364-5
                                                      diving reflex 289
decorin 41
                                                      dobutamine 276
deformities, right of action 354-5
                                                      doctors
delivery
                                                        clinical judgement 378
  iatrogenic 1, 2, 4, 5-6
                                                        developments in practice 349-50
  immediate versus delayed 177-9, 194
                                                        disclosure to patients 331-2
  management 204-5
                                                        duty of care to parents 391
  mode 184-5
                                                        junior practitioner 350-1
    anaesthesia provision 252
                                                        newly qualified 350-1
    intracranial trauma risk 254
                                                        obstetricians 322-3
                                                        professional judgement 377-8
    IUGR 228
    pre-eclampsia 225
                                                        professional opinion differences
                                                             377-8
    preterm breech 205
    vertex presentation 205
                                                      doctrine of necessity 341
  pre-eclampsia 225
                                                        Scotland 342-3
  see also preterm delivery
                                                        treatment of child 368
dermatan 38-9
                                                      doctrine of res ipsa loquitur 350
dermatan sulphate 41
                                                      doctrine of strict liability 346
dermatan sulphate proteoglycan II 41
                                                      dopamine 276
developmental quotient (DQ) 118
                                                      double-stranded oligodeoxynucleotides (ODN)
dexamethasone
  anaesthesia in preterm labour 249
                                                      drugs
                                                        administration
  antenatal use 182-3
  IL-8 inhibition 91
                                                           neonates 269-71
  maternal therapy 202-3
                                                           pregnancy 238-9
  NF-\kappaB effects 91
                                                        pharmacology in pregnancy 238
diabetes mellitus 158
                                                      drugs, recreational 154-6
  anaesthesia in preterm labour 249
                                                      ductus arteriosus
  \beta sympathomimetics 196–7
                                                        patent 275-6
  prophylactic medical care 159-60
                                                          adverse effects 275-6
  steroid contraindications 203
                                                        premature closure 199-200
diacylglycerol 34-5
                                                      duty of care 345-6
digital examination
                                                        breach 346, 349
  membrane rupture diagnosis 171-2
                                                        developments in practice 349-50
  preterm labour 191
                                                        nature and extent 370
disability 109, 117
                                                        negligence 346
  outcome 116
                                                        to parents 391
  overall severe 117-18
                                                      dyspraxia 123
  prematurity 174-5
  quality of life 375-6
                                                      eclampsia 222
  rate 109-15
                                                      economic evaluations 315-16
  substituted judgement 376-7
                                                        stages 315-16
  see also neurological disability
                                                        types 315
discharge arrangements for neonates
                                                      economics of service provision 315-20
                                                        interest 317-18
    293
```



eicosanoids 36–7	feeding problems 122
elastase 36-7, 40	peri-viable 294–5
elastin 39–42	
elective delivery see iatrogenic delivery	Family Law Reform Act (1969) 344
embryo	family life, respect for 388-9
decisions made by mother 334	feed tolerance 279–80
legal standing 334	feeding
emergency treatment 343	difficulties 121–2
emotional support, maternal 254	failure to 384–5
encephalopathy	intolerance 279
Caesarean section risk 184–5	neonates 277–83
neonatal with IUGR 227	problems 122
endoscopic repair of membranes 183	fentanyl 255
endothelin receptors 34–5	fetal distress
endothelins	intrapartum 227
myometrial contraction 34–5	labour with pre-eclampsia 223
myometrial stimulation 53	fetal membranes 48–9
endotoxins 9	changes in labour 76–7
intra-amniotic 176–7	relaxin in maturation 143-4
enteral nutrition 277-8	tensile strength 48–9
minimal 279–80	see also membrane rupture; premature rupture o
environmental pollution 17	membranes; preterm premature rupture of
ephedrine 242	the membranes (pPROM)
epidural analgesia	fetal monitoring
fetal temperature increase 248–9	anaesthesia 237, 253
post-operative 239	intrapartum 204–5
preterm labour 254, 255	parents' wishes 323–4
vasodilatation 242	fetus
epidural haematoma 246	compromise in maternal pulmonary
epinephrine, see adrenaline	hypertension 240
erythromycin	decisions made by mother 334
mode of action 181	deteriorating condition 5
preterm labour use 204	growth restriction 154–5
prophylactic 180–1	inflammatory response 171
erythropoiesis 280	legal standing 334–5, 339
erythropoietin, recombinant 281	management recommendations 321
Escherichia coli 283–4	maternal behaviour modulation 336–7
ethics, status of fetus/embryo 334	medical intervention 337
European Convention on Human Rights 338, 387	negligence causing death 353
entitlement to life 368–9	safeguarding 336–7
parental responsibility 366	treatment as person with rights 335–6
parental rights 388–9	ultrasound imaging 214–16
expert evidence 347–8	viability 1
extended perinatal mortality rate (EPMR) 114	wellbeing in multiple pregnancies 214–16
extremely low birthweight babies	fibroblasts, cervical 39
behavioural outcomes 125	fibronectin, fetal 320
cognitive ability at school age 123–4	bedside testing 134–5
deaths 112–13	cervical length combination 147
motor function 123	cervico-vaginal secretions 134–5, 192–3
extremely preterm infants	clinical utility 134–5



fibronectin, fetal (cont.)	growth
membrane content 48-9	catch-up 126–7
multiple pregnancies 212	restriction 110, 114
predictive value 134, 146	school age children 126-7
preterm uterine activity 147	
fluids	haematological scoring systems, neonatal 284-5
management guidelines 278	haemodialysis, chronic 247
neonates 277	haemoglobin 280-1
withdrawing/withholding 370-1	haemostatic function 199-200
see also hydration	harm
folic acid supplementation 293	establishment 352–3
follow-up compliance 115	liability 346
food see nutrition	serious 372
forced expiratory volume in 1 second (FEV1)	healthcare team
122–3	consensus approach 383
forced vital capacity (FVC) 122-3	disagreement with parents 373
fungaemia 283–4	see also doctors; nurses; staff, hospital
funnelling of cervix 137, 171–2	health-related quality of life 126
8	hearing impairment 119
galanin 30	heart disease, congenital maternal 241
gamete intrafallopian transfer (GIFT) 158–60	heart rate, fetal
gap junctions 27, 37	anaesthetic drugs 237
Gardnerella vaginalis 6, 55–6	auscultation 214–16, 323–4
gastrin-releasing peptide 30	continuous electronic monitoring 227
gastrointestinal colic 194	heat loss 261–5
gastro-oesophageal reflux 122	neonates 272
genital tract infection 154–5	HELLP syndrome (haemolysis, elevated liver
multiple pregnancies 216	enzymes and low platelets) 222, 224
germinal matrix	delivery 245
bleeding 287–90	pre-eclampsia 244–5
haemorrhage 289–90	heparan sulphate 38–9
gestational age 1, 110	heparin 38–9
calculation 324	_
determination 3–4	home uterine activity monitoring (HUAM)
	home-based care 320
legal definitions 2 lower limit 2–3	
	hospitals
multiple birth delivery 211, 219	admissions 317
preterm delivery risk 133	bed occupancy 309–10
preterm labour 191	service economics 317
steroid benefits 203	see also staff, hospital
Geudel airway 265–6	host defences, immature 284
Gillick competence 343–4	human chorionic gonadotrophin (hCG) 161
glucocorticoids 86, 97	human rights 338
antenatal 183	decision-making 377
glyceryl trinitrate 36, 160	parental responsibility 366
glycosaminoglycans 38–42	principles 387
fibroblast production 45	see also European Convention on Human Right
G-proteins 30	Human Rights Act (1998) 387–8
granulocyte colony-stimulating factor (G-CSF)	humidification, environmental for neonate 272
predictive value 145	hyaluronic acid 38–9, 41



hydralazine 243	immunosuppressive treatment 247–8
hydration 202, 384–5	incubators
benefits 385	temperature control 272
burdens 385	indomethacin 160
as medical treatment 384	anaesthetic implications 251
withholding 370–1	medical emergencies 237
hydrocephaly, post-haemorrhagic 290	patent ductus arteriosus closure 276
hydrocortisone 277	polyhydramnios 217
$^{-1}$ 17 $lpha$ -hydroxyprogesterone caproate 32	renal function 199–200
15-hydroxyprostaglandin dehydrogenase (PGDH)	tocolysis 182, 199–200
34, 77–8	Infant Life Preservation Act (1929), child
expression 88	destruction offence 390–1
function 88–9	infections 6–10, 54–6
isoforms 88–9	amniotic fluid proinflammatory cytokines 144
promoter 88–9	cause of death 174–5
hyperactivity 125	clinical signs 173
hyperbilirubinaemia 283	extra-uterine 9–10
hypercaloric feeding 279–80	fetal
hyperoxia 267	assessment 173
hypertension	biophysical score 173–4
anaesthesia in preterm labour 249	hypoxia-ischaemia combination 184
*	genital tract 154–5
planned preterm delivery 242–5	intra-amniotic 171
pre-eclampsia 222–3	
pregnancy 158	intrauterine 8–9, 287–90
hyponatraemia 277	lower genital tract 6–8
hypotension	lower respiratory tract 122
neonates 276–7	materno-fetal 171
regional anaesthesia 251	diagnosis 172–4
hypothermia prevention 261–5	neonatal 283–6
hypovolaemia correction 276	prevention 286
hypoxia 37	prophylactic antibiotics 180-1
fetal 177	susceptibility 284
fetal stress 184–5	nosocomial with parenteral nutrition 277–8
intrapartum 228	organism cultures 285–6
IUGR 227, 228	systemic 158
neonatal acidosis 270–1	inflammation/inflammatory response, fetal 171
placental bed 222–3	assessment 173
resistance 288–9	detection 173–4
hypoxia-ischaemia, brain sensitisation 184	inflammatory cells 76–7
	inflammatory mediators 46–7
iatrogenic delivery 1, 2, 4, 5–6	myometrial contraction 36-7
preterm 225, 228	information for parents 367
ibuprofen 276	inhibitory proteins (I κ Bs) 81–2
idiopathic preterm delivery 6	inositol 1,4,5-triphosphate 32–3, 34–5
black population 155	inpatient management of preterm labour 194
IκB kinase complex (IKK) 81–2, 97	insulin release 196–7
$I\kappa B\beta$ protein 95, 97	intellectual impairment 118
ileal perforation, indomethacin-induced 199–200	intensive care
immaturity 109–10	adult facilities 312
blindness 118–19	see also Neonatal Intensive Care Unit



interleukin 1(IL-1)	jaundice
membrane rupture 50–1	causes 282
prostaglandin production 53	neonates 282
interleukin 1β (IL- 1β) 36–7, 46–7	risk factors 282
bronchopulmonary dysplasia 176-7	side effects of treatment 283
up-regulation in labour 96	treatment threshold 283
interleukin 6 (IL-6) 36–7, 46–7	judgements, substituted 376-7
amniotic fluid levels 144	jugular vein, internal, cannulation 243–4
bronchopulmonary dysplasia 176-7	, c
neonatal assay 285	kernicterus 283
periventricular leukomalacia 175–6	killing
prostaglandin production 53	active 370–1
interleukin 8 (IL-8) 36–7, 46–7, 77, 89–92	intentional 371–2
bronchopulmonary dysplasia 176–7	Kleihauer test 191
neonatal assay 285	kyphoscoliosis 246–7
production 90	Nyphotoniono 210 /
during labour 91–2	labetolol 243
promoter binding sites 90–1	labour
interleukin 8 (IL-8) gene 90	induction 225
expression 90	maternal hypertension 242–3
interleukin 10 (IL-10) 97	management 204–5, 329, 338–9
interventions for benefit of adult 342–3	onset
intraparenchymal haemorrhage 289–90	
	transcription factors 93
intrauterine death, multiple pregnancies	triggers 52–3
216–17	precipitation risk 236–9
intrauterine growth restriction (IUGR)	term 52–4
159, 225–8	see also preterm labour
aetiology 225–6	labour-associated proteins 76–7
corticosteroids 227	laparoscopic surgery 239
definition 225–6	laser therapy for retinopathy of prematurity 287
delivery 228	left handedness 123
elective 228	legal issues see treatment, legal issues
diagnosis 226	leukocytes 36–7, 46–7
extremes of viability 228	cervical ripening 53
incidence 226	protease-producing 45
management 226–8	liability, no-fault 357–8, 359
monitoring 227	life, obligation to protect 387
placental insufficiency 223	life-prolonging treatment 382–3
pre-eclampsia 223	lifestyle modification 154-8
tocolysis 226–7	lipopolysaccharide 55-6, 79-80, 83
transfer to neonatal intensive care 227-8	Listeria monocytogenes 9
intrauterine infection 8-9, 287-90	litigation costs 308
intraventricular haemorrhage 174-5, 289-90	L-NAME 47–8
antenatal glucocorticoids 183	London Regional Specialised Commissioning
patent ductus arteriosus 275-6	Group (LRSCG) 308-11
steroid prophylaxis 182-3, 202-3	lung(s)
intubation, neonates 267–8	fetal maturity 214–16
in vitro fertilisation (IVF) 158-60	corticosteroids 223–4
IQ levels 118, 127	cost effectiveness 319-20
iron supplementation 281, 293	inflation pressure 266–7



injury 176–7	technique varying 350
maturation enhancement 183	membrane rupture 48–52
see also pulmonary entries	biochemical events 50-1
lung disease, chronic 120-1, 122-3	diagnosis 171–2
adolescents/young adults 127	endoscopic repair 183
CPAP use 267–8	morphological changes 49-50
fetal exposure to inflammation 176-7	zone of altered morphology 49-51
materno-fetal infection 171	see also premature rupture of membranes;
mechanical ventilation 273-4	preterm premature rupture of the
school age children 122-3	membranes (pPROM)
steroid therapy 274–5	Mental Incapacity Bill 341-2
lung disease, restrictive in pregnancy 246–7	mesenteric artery, superior, flow velocity 279
lung function tests	mifepristone 32
adolescents/young adults 127	miscarriage
school age children 122–3	risk with anaesthesia 237
luteolysis induction 83	see also stillbirth
•	morbidity
macrophages 55-6	bias 110
magnesium sulphate 160	maternal 310
adverse effects 200–1	neonatal 179
anaesthetic implications 251	pulmonary insufficiency 177-8
corticosteroid combination 224–5	short-term 119–22
medical emergencies 237	mortality
pre-eclampsia 224–5, 244	bias 110
tocolysis 182, 200–1	outcome studies 115
malabsorption, short bowel syndrome 121–2	prematurity 174–5
malpresentation	rate 112–13
IUGR 228	steroid prophylaxis 182–3
multiple births 220-1	studies 116
managed clinical networks 309–10, 314	time of death 112–13
guidelines 310	motor coordination, fine 123
management strategies, cost effectiveness 318–20	motor disability, periventricular leukomalacia 292
manslaughter prohibition 368–9	multi-organ dysfunction 222–3
marital status 14	multiple births 4, 13
maternal age 13-14	Caesarean section 218
maternal disease management 158–60	diamniotic preterm first twin breech 220
maternal/fetal conflict 338	diamniotic very low birthweight 219
maternal-placental perfusion 216	higher-order 220–1
maternity services 310–11	limits of viability 221
guidelines 310–11	risks 221
matrix metalloproteinase (MMP) 40, 46–7	care in different neonatal units 307
membrane rupture 50–1	cord entanglement 220–1
preterm prelabour 51	delivery
matrix metalloproteinase 8 (MMP-8) 89–92	gestational age 211, 219
upregulation in labour 96	limits of viability 221
matrix metalloproteinase 9 (MMP-9) 145	mode 218–21
medical emergencies 236–7	diamniotic
preterm labour prevention 237	preterm first twin breech 220
medical practice	very low birth weight 218–19
practitioner responsibilities 349–50	limits of viability 221



multiple births (cont.)	myometrium
locking 220–1	cholinergic stimulation 30
malpresentation 220–1	electrical activity 28
medical staffing 221	function control 30, 31
monoamniotic 220	hormonal modulation 30–7
outcome assessment 114	labour onset 76
resuscitation equipment 261–3	neuronal modulation 30
triplets 220–1	oxytocin sensitivity 197–8
vaginal delivery 218	smooth muscle 27–8
risks 222	contractility 161–2
see also twin pregnancy	stretch 94–5
multiple pregnancies 12, 13, 37, 210–21	myosin 28
aetiology 210–11	myosin light chain kinase (MLCK) 28, 29
bed rest 212–13	myosin light chain phosphatase (MLCP) 161–2
cervical cerclage 211–12, 213	myosin light chains, dephosphorylation 29
cervical length 141	my com ngm chams, dephotophoty auton 2)
chorioamnionitis 216, 221	naloxone 270
complications 214	naproxen 251
corticosteroids 214–16	nasal intermittent positive pressure ventilation
fetal fibronectin 212	(NIPPV) 274
genital tract infection 216	nasciturus principle 356
home uterine activity monitoring 212	national cohorts 111
incidence 210–11	necrotising enterocolitis 121–2, 278–80
intrauterine death 216–17	co-amoxiclav 181, 204
	indomethacin-induced 199–200
investigations 215	patent ductus arteriosus 275–6
threatened preterm labour 214–16 observations 215	1
	negligence
perinatal morbidity/mortality 210–11	causation 351–2
placental abruption 216	causing death of fetus 353
polyhydramnios 217	child born injured 354–5
prenatal care 212	contribution to injury 351
preventive strategies for preterm labour 212–14	costs of claims 357–9
risk prediction 211–12	duty of care 345, 346
tocolysis 213, 217	gross 372
transfer to neonatal unit 217–18	liability in obstetric care 345–57
treatment of threatened preterm labour	medical professional 347–8
216–18	reform of actions 357–9
ultrasound assessment 211-12	relationship between wrongdoer/harmed 346
uterus over-distension 211	Scottish law 356–7
see also twin pregnancy	statutory offence 372
murder	Neisseria gonorrhoeae 55–6
attempted 384–5	neonatal care categories 308-9
prohibition 368–9	Neonatal Intensive Care Unit
mycoplasmas, genital 8	admission 271–2
myometrial contractions 26	cot blocking 307
cervical tissue 89–92	neonatal life support algorithm 263-4
fundally dominant 76	neonatal management, differences over time
metabolic modulation 37	111–12
oxytocin stimulation 32-3	neonatal services, specialist 313
strenoth 191	neonatal unit needs 307



neonates	inhibition 96–8
abnormalities and right of action 354-5	pathway 82–3
born injured through negligence 354-5	PGDH downregulation 88–9
cardiovascular system 275–7	preterm delivery prevention 96–8
discharge arrangements 293	therapeutic target 97
electrolytes 277	NHS Redress Scheme 358
feeding 277–83	nifedipine 160, 243
fluids 277	anaesthetic implications 252
infections 180–1, 283–6	dosage 199
jaundice 282	maternal side effects 198-9
long-term follow-up 295–7	multiple pregnancies 217
management	tocolysis 198
recommendations 321	nimesulide 200
until discharge 271–82	Nitrazine test 171–2
neurological screening 287–90	nitric oxide
nutrition 277–83	L-arginine system 47–8
outcome	cervical ripening 47–8
interventions 182–4	donors 35, 36, 160, 201
predelivery interventions 201-4	myometrial contractility 35-6
prophylactic antibiotics 180-1	nitric oxide synthase 35–6
peri-viable 294–5	'no chance' situation 382–3
physiological condition 254	'no purpose' situation 382–3
predischarge arrangements 287–93	no-fault liability 357-8, 359
respiration 272–5	non-resuscitation 383
support withdrawal 324-5	non-steroidal anti-inflammatory drugs (NSAIDs)
thermal environment 272	77, 238–9
transfusion 280–2	nuclear factor kappa B see NF-κB
see also resuscitation	nurses
neonaticide 383–4	recruitment/retention 312-13
neonatologists, obstetrician collaboration 322-3	specialist 307
Neopuff flow-controlled pressure-limited device 266	nutrition 16, 384–5
neurological disability	artificial 384
IUGR 227	benefits 385
materno-fetal infection 171	burdens 385
NHS Redress Scheme 358	as medical treatment 384
neurological screening of neonates 287–90	neonates 277–83
neuronal migration abnormalities 287–90	withdrawing/withholding 370-1
neuropeptide Y 30	nutritional status 154–5
neutrophils 89–90	
neonatal transfusion 286	obstetricians
NF-κB 81–2, 94–5	neonatologist collaboration 322-3
activation in amnion in labour 95	preliminary discussion 323
amnion cells 88–9	obstetrics
AP-1 cross-coupling 95	economics 317–18
bacterial endotoxin 83	liability for negligence 345–57
binding blocking 97	occupation, maternal 16, 154-5
COX-2 promoter 85–6	oestradiol 45
dexamethasone effect 91	labour onset 52–3
double-stranded oligodeoxynucleotides 97	pregnancy levels 241–2
functions 95	17β -oestradiol 30–2



oestriol (E3) 30-2, 142-3	myometrium sensitivity 197-8
oestrogen	oxytocin antagonists 160, 197-8
cervical ripening 45	multiple pregnancies 217
myometrial contractility 30	tocolysis 182
oestrogen receptors 142–3	oxytocin receptor 33, 77, 92–3
oligohydramnios 175	AP-1 binding site 94
indomethacin-induced 199-200	mRNA downregulation 93
IUGR 228	promoter 92–3
neonatal outcome 183	
prognosis for survival 178	pacemaker cells, myometrial 28
ultrasonography 171–2	packed red blood cell transfusion 280
umbilical cord compression 177	pain, human rights issues 388
oliguria 243–4	palliative care 371–2
operative delivery 5-6	parens patriae jurisdiction 340-1
see also Caesarean section	parenteral nutrition 277–8
opiate abuse 16–17	parents
opioids 238–9	advance authorisations 324-5
organ transplantation 247–8	best interests of child 373-5
osteonectin 49–50	clinical trials agreements 377
osteopenia of prematurity 277–8	consensus approach 383
outcome(s) 3	consent 344, 366–8
oligohydramnios 183	decision-making 321-3, 367
resource allocation 392-3	involvement 367–8
reviews 109–15	treatment 365
outcome measurement 1	disagreement
adolescence 127	with healthcare team 373
adults 127	with professional opinion 380-1
denominator 112	fetal monitoring 323-4
disability 116	human rights 388–9
follow-up compliance 115	information
growth restriction 114	needs 367
hospital-specific 110-11	presentation 295–6
lethal congenital malformations 115	post-operative care commitments 381-2
mortality rate 115	preliminary discussion 323
multiple births 114	preparation for preterm labour 202
national cohorts 111	preterm infant discharge 293
peri-viable neonates 294	quality of life judgement for child 381-2
racial characteristics 114-15	responsibility 366
regional-specific 110-11	rights over children 367
school age 122–7	parity 12
time period of study 111–12	patient-controlled analgesia 238-9
outpatient management of preterm labour 194	patients
oxygen	decision-making 332
dependency 119, 120–1	information
home 120–1, 295–7	requirements 330-2
resuscitation 267	on risks 331
saturation level 293	medical advice acceptance 337
oxytocin	refusal to cooperate 337
delivery expediting 178	D-penicillamine 287
myometrial contraction 32–3	penicillin, mode of action 181



perinatal centres 311	plasminogen activators 36–7
accommodation of mother 311-12	platelet activating factor (PAF)
transfers 324	myometrial stimulation 53
perinatal mortality, extended rate 114	prostaglandins
periventricular haemorrhage 287–90	production 53
autoregulation 289	synthesis stimulation 85
classification 289	platelets 183
clinical features 290	pneumoperitoneum, carbon dioxide 239
complications 290	pneumothorax
phenobarbital 204	patent ductus arteriosus 276
periventricular leukomalacia 175-6, 287-90	surfactant administration 269
betamethasone 183	pollution, environmental 17
chorioamnionitis 291–2	polyhydramnios, multiple pregnancies 217
histopathological changes 291	postgraduate training 313–14
lesion distribution 291	post-operative care, parental commitment 381-2
motor disability 292	postpartum haemorrhage, multiple births 221
prevalence 291	prediction of preterm labour
permanent vegetative state 376, 380, 385	cervical ultrasound 136-42
peroxisome proliferator activator receptor (PPAR)	endocrine factors 142–5
82–3	fetal fibronectin 134–5
bacterial endotoxin 83	marker combination 146-7
peroxisome proliferator response elements (PPREs)	risk scoring 133
82–3	uterine activity monitoring 135–6
pH, uterine 37	predischarge arrangements, neonates 287–93
phenobarbital 204	pre-eclampsia 222–5
phosphate supplementation 277–8	aetiology 222–3
phospholipase A ₂ 9, 77–83	clinical features 243
activation 79–80	coagulopathy 244–5
C/EBP binding sites 81	criteria 224
cytosolic 78–9, 80	definition 222–3
binding sites 80–1	delivery 225
promoter 80	general anaesthesia 245
rapid 80	gestation
sPLA ₂ gene induction 82	greater than 34 weeks 223
expression 79	up to 34 weeks 223–4
secretory 78–9, 81	hypertension 222–3
bacterial endotoxin 83	iatrogenic preterm delivery 225
gene induction 82	incidence of preterm labour 223
phospholipases 55–6, 77–8	indications for delivery 244
phosphorus metabolites 37	intrauterine growth retardation 223
phototherapy 283	magnesium sulphate 224–5
placental abruption 51, 223–4	management of preterm labour 223–5
Caesarean section 216	placental insufficiency 223
multiple pregnancies 216	planned preterm delivery 242–5
pPROM 177	severe 223–4
placental bed, hypoxia 222–3	tocolysis 223–4
placental dysfunction, viral infections 8	pregnancy
placental insufficiency, pre-eclampsia 223	behaviour of women 334
placentation, abnormal 222–3	brain death 246
planning advance for complex cases 322–3	cardiac arrest 245–6



pregnancy (cont.)	management
cervix 35, 39–42	economics 319–20
competence absence 340-2	pre-eclampsia 223–5
complications 194	onset prevention 160-2
drug administration 238-9	problems 254
hypertension 158	preterm premature rupture of the membrane
interval 12	(pPROM) 8–9, 48, 51, 171
management 329, 332-7	between 25 and 31 weeks gestation 178-9
medical disorders 158	at 32–6 weeks 179
persistent vaginal bleeding 159	amnioinfusion 183
previous second trimester loss 159	cervical cerclage 183-4
problems 337	conservative management 178-9
prophylactic medical care 159-60	delivery mode 184–5
screening 332–4	diagnosis 171–4
stress 156–7	endoscopic repair 183
see also multiple pregnancies	before fetal viability 177–8
premature rupture of membranes 48	IL-6 levels 144
C-reactive protein 173	immediate versus delayed delivery 177-9
see also preterm premature rupture of the	inpatient management 179-80
membranes (pPROM)	materno-fetal complications 174-7
prematurity 174–5	outpatient management 179-80
prenatal care of multiple pregnancies 212	perinatal survival 177–8
preterm delivery	previous 11
causes 5–10	prophylactic antibiotics 164
counselling 323–4	private life, respect for 388–9
definition 1–3	professional guidance, legal opinion 382-4
economics 318	professional opinion
iatrogenic 225, 228	differences 377–8
idiopathic 6	parental disagreement 380-1
black population 155	progesterone
incidence 1, 4–5, 153–4	cervical ripening 45–6
management recommendations 320-5	functional withdrawal 96
planned 239-48	IL-8 inhibition 91
fetal reasons 240	isoforms 96
maternal reasons 240–8	labour 95–6
previous 10–11	myometrial contractility 30
risk factors 248–9	cPLA ₂ inhibitor upregulation 80
risk with anaesthesia 237, 248-9	withdrawal theory 53-4
team planning 240	progesterone receptors 32
preterm labour	function 96
anaesthetic implications 249-52	prognosis 364–5
clinical assessment 191, 192	lack of certainty 377
counselling 323–4	uncertain 373–4
detection 319	prognostic significance 2
diagnosis 191–4	prostaglandin(s) 9
differential 194	amnion as source 84
investigations 192–3	biosynthetic pathway 77–8
incidence with pre-eclampsia 223	cervical changes 76–7
inevitable 248–9, 253	cervical ripening 44–5
investigations 191–3	delivery expediting 178



ductus arteriosus patency 199–200	disability 375–6
glucocorticoid inhibition 86	evaluation of expected 374-5
labour onset 53	expectation 375–6
myometrial contraction 33-5	judgements 364–5, 374, 375
prostaglandin D synthase (PGDS) 87	life-saving/prolonging treatments 380
prostaglandin D ₂ 77–8	objective 126
prostaglandin dehydrogenase 88–9	parental judgement 381–2
chorionic 53	resource allocation 392–3
prostaglandin E synthase (PGES) 87	school age children 126
membrane-associated 87	
prostaglandin E ₂ 34, 77–8	race of mother 14–15, 155
cervical ripening 44–5	racial characteristics 114-15
MMP activity 50–1	referral centres 110–11
production inhibition 86	rehospitalisation 122
synthesis 33–4	relaxin 46
prostaglandin F synthase (PGFS) 87	predictive value 143–4
prostaglandin $F_{2\alpha}$ 34, 77–8	relaxin receptors 143–4
cervical ripening 44–5	renal disease 158
MMP activity 50–1	maternal 247
prostaglandin I synthase (PGIS) 87	renal function 199–200
prostaglandin I ₂ 77–8	reproductive disorders 158–60
cervical ripening 44–5	res ipsa loquitur doctrine 350
prostaglandin synthases 87	research
prostaglandin synthesis inhibitors 199–200	base 314
haemostatic function 199–200	economics of obstetrics 318
side effects 200	resource allocation 365, 391–3
prostaglandin synthetase inhibitors 251	Jaimee Bowen case 378
proteases 9, 51	outcomes 392–3
protein kinases 80	quality of life 392–3
proteoglycan, cervical 41–2	respiration, neonates 272–5
pseudomembranous colitis 181	respiratory disease, maternal 246–8
psychiatric disease 15	respiratory distress syndrome 111–12, 174–5
psychological stress 156–8	anaesthesia in preterm labour 249
pulmonary dysfunction, adolescents/young adults 127	lung injury 269
pulmonary hypertension	prematurity-related 179
maternal 240, 241	prevention 134–5
persistent 199–200	risk 269
pulmonary hypoplasia, oligohydramnios 175	steroid prophylaxis 182–3, 202–3
pulmonary insufficiency 174–5	respiratory support, air versus oxygen 267
morbidity 177–8	respiratory symptoms, chronic at school age
pulmonary oedema	122–3
β-adrenergic agent therapy 250–1	respiratory syncytial virus (RSV) 122
β sympathomimetics 217	resuscitation 260–71
magnesium sulphate with corticosteroids 224–5	air versus oxygen 267
maternal hydration effect 202	airway 265–6
pre-eclampsia 223–4, 243–4	anticipation 260–1
pyelonephritis 9, 158	at birth 389–91
	breathing 266–8
quality of life	counselling 324–5 decision not to 295–324–5–383
aeasian-making 3/3-b	decision not to 295, 524-5, 585



resuscitation (cont.)	maternal 178
equipment 261–3	neonatal clinical features 284-5
futile treatment 379–80	service(s)
high-risk infants 260-1	guidelines 310
human rights issues 387	integrated 309–10
hypothermia prevention 261–5	requirements 307–14
initial assessment 265	service infrastructure 309–10
limit absence 294–5	change implementation 314
personnel 261–4	service provision economics 315–20
preparation 261–4	hospitals 317
procedure 261	sex, fetal 17
retinopathy of prematurity 117, 118–19, 121	short bowel syndrome 121-2
autism risk 125–6	small for gestational age fetus 225-6
interventions 287	smoking 15, 16
ophthalmological surveillance 295-7	risk factor 154–5
patent ductus arteriosus 276	social deprivation 156
risk 287	smooth muscle
review groups 308–9	cervical 39
Rho A 161–2	contractility 161-2
Rho associated coil-forming protein kinase (ROCK	social support, enhanced 157–8
I and II) 161–2	sociodemographic risk factors 13–15, 17
Rho kinase inhibitors 161–2	socioeconomic factors 154–5
risk factors for preterm delivery 3, 10–18	stress 157–8
epidemiological 153, 154	socioeconomic status 4, 14–15
maternal 10–18	sodium bicarbonate 270–1
ritodrine 160, 195–6	spinal analgesia 242
anaesthesia in preterm labour 250–1	spiral artery conversion failure 222–3
fetal effects 197	spontaneous delivery 1
infusion 197	staff, hospital 272
maternal effects 196–7	counselling 295–6
pre-eclampsia 223–4	requirements 312–13
side effects 196	resuscitation 261–4
	see also doctors; nurses
sanctity of life principle 374–5	standard of care 346-50
sarcoplasmic reticulum 29	standard practice, departure from 349
school age, outcomes 122–7	staphylococci, coagulase-negative 283-4
scoring system, preterm delivery risk 133	Staphylococcus aureus 283–4
Scotland	steroid hormones 95–6
children 344–5	see also corticosteroids
common law 356–7	stillbirth
doctrine of necessity 342-3	definition 390
emergency treatment 343	IUGR 227
interventions for benefit of adult 342–3	strabismus 121
young people 344–5	streptococcus group B 7
screening tests 332–4	stress 15
availability 333–4	pregnancy 156–7
choice 333	psychological 156–8
preterm delivery risk 133	socioeconomic factors 157–8
selection bias 112	strictures, intestinal 121–2
sensis 283–4	subclavian vein cannulation 243–4



subependymal haemorrhage 289–90	tissue inhibitors of metalloproteinase (TIMP) 46–7
substance abuse 16–17	membrane rupture 50–1
substance P 30	tissue use constraints 324–5
succinylcholine 251	tocolysis/tocolytic agents 31
suffering, human rights issues 388	anaesthesia in preterm labour 249-52
sulindac 217	beneficial effects 195
surfactant therapy 269	cervical ripening 38
antenatal steroids 271	chorioamnionitis treatment 182
neonates 272–3	contraindication 182
racial characteristics of babies 115	placental abruption 216
steroid use 203	intrauterine death in multiple pregnancy
types 269	216–17
ventilated babies 111–12	intravenous access 214–16
surgery	IUGR 226–7
fetal monitoring 237	magnesium sulphate 224-5
laparoscopic 239	multiple pregnancies 213, 217
service organisation 308	pre-eclampsia 223–4
survival	preterm labour
benefit to child 380	onset prevention 160–2
harm to child 380	threatened 194-201
neonatal 153-4, 174-5	prophylactic 160-2
oligohydramnios prognosis 178	T-piece breathing device 266
perinatal following pPROM 177-8	training, postgraduate 313–14
rate 109–15	transcription factors, labour onset 93
resuscitation 260–1	transfer
swallowing problems 122	counselling 324
symphysis pubis pain 194	delayed with pulmonary oedema 243-4
systemic lupus erythematosus (SLE) 17, 158	disadvantages 307
prophylactic medical care 159-60	intrauterine 324
	to neonatal unit 217–18
tachycardia 275	neonatal intensive care 227-8
tachypnoea 275	postnatal 324
temperature, environmental for neonates 272	pre-eclampsia 223–4
temperature, fetal increase with epidural analgesia	transport services 311–12
248–9	transfusion
terbutaline 160	neonates 280–2
Δ^9 tetrahydrocannabinol (D ⁹ – THC) 156	response to 280–1
thalidomide 354	risks 281
Thames Regional Perinatal Group (TRPG)	transport services 311–12
308-11	treatment, legal issues 364–5
thrombin, placental abruption 51	assault 380
thrombocytopenia 224	benefits 365, 375, 379, 380, 385
neonatal sepsis 284–5	burdens 375, 379, 385
pre-eclampsia 244–5	court distinction from intentional killing 371-2
thromboembolism, maternal 246	criminal law limitations 368-72
risk 247–8	damages 353, 356-7
thromboxane 77–8	decision-making 364–5
thromboxane synthase (TXS) 87	disagreements 372–3
thyrotrophin releasing hormone	futility 364–5, 379–80, 387
(TRH) 203-4	given in best interests 341



treatment, legal issues (cont.)	umbilical artery, absent end-diastolic
harms 365, 380	flow 279
inappropriate 388	umbilical cord compression 177
legal principles 366–8	'unbearable' situation 382-3
life-prolonging 380, 387	Ureaplasma urealyticum 55–6
life-saving 380	urinary tract infection 158
litigation costs 308	uterine activity
no-fault liability 357–8, 359	contractile 26–7
professional guidance 382-4	home monitoring 212
refusal 343–4	monitoring 135-6
relative efficacy 377	preterm 147
utility 364–5	uterus
withdrawing/withholding 380	over-distension 211
resources 392–3	palpation 191
see also common law; competence; courts;	physical abnormalities 17
damages; negligence; Scotland	
Trichomonas vaginalis 55–6	vaginal bleeding, persistent in pregnancy
tumour necrosis factor (TNF) 53	159
tumour necrosis factor α (TNF α) 36–7	vaginal delivery
MMP-1 production 51	intracranial trauma risk 254
turquoise light phototherapy 283	maternal hypertension 242-3
twin pregnancy 159	multiple births 218
diamniotic 210	risks 222
delivery 218–19, 220	vaginal secretions, fetal fibronectin 134-5
dichorionic 216–17	vaginal speculum examination 191
dizygotic 210	vaginosis, bacterial 6-7
locked twins 220	vasoactive intestinal peptide 30
monoamniotic 210	ventilated babies, surfactant therapy
delivery 220	111–12
monochorionic 210, 216–17	ventilation, maternal 239
cerebral palsy risk 291	ventilation, mechanical 273-4
monozygotic 210	conventional 273-4
	high-frequency oscillatory 273-4
ultrasound imaging 3, 4, 110	human rights issues 387
biometry 225–6	pressure effects in neonate 267–8
cervical length 163-4, 171-2, 193	pressure-cycled 273-4
cervix 136–42, 159–60	withdrawal 379, 383
dilatation 171–2	withholding 380
cranial 291, 291–2	very low birthweight babies
fetal assessment 173-4, 214-16	cognitive ability at school age 124
multiple pregnancies 211–12	deaths 112–13
oligohydramnios 171–2	dyspraxia 123
preterm labour 191	home oxygen 120–1
three-dimensional 138	oxygen dependency 120-1
translabial in membrane rupture diagnosis	racial characteristics 115
171–2	viability 3
transvaginal 136	extremes 228
cervical canal length 163-4	limits and multiple birth delivery 221
cervix 159–60	viral infections 8
membrane rupture diagnosis 171–2	vitamin supplements 293



417 Index

weighing neonates 272, 277 see also birthweight wheeze 122–3 white cell count 284–5 wrongful birth cases 352 wrongful life actions 352-3, 355-6

Y-27632 Rho kinase inhibitor 161–2 young people, competence 343–5

zone of altered morphology (ZAM) 49-51